Immunomedics inks deal with Syncor
Philips signs off on CEO’s replacementImmunomedics has announced that Syncor International will distribute the radiopharmaceutical firm’s CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year
Philips signs off on CEOs replacement
Immunomedics has announced that Syncor International will distribute the radiopharmaceutical firms CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year with Bergen Brunswig (SCAN Special Report 6/98), which replaced a prior arrangement with Mallinckrodt.
Bergen Brunswig will provide nonradiolabeled CEA-Scan to Syncor, which will radiolabel the CEA-Scan with technetium at its 118 U.S. radiopharmacies, according to an Immunomedics spokesperson. Syncor, of Woodland Hills, CA, will then provide CEA-Scan to its customers in ready-to-use dosages. Syncor will also support Morris Plains, NJ-based Immunomedics with its own sales force.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
